Camurus Ab · OMXSTO:CAMX
Camurus Ab — Shareholder Meeting (May 2024)
25 slides from Camurus Ab's shareholder meeting presentation, May 8, 2024
Slide 1: Annual General Meeting 2024 – CEO presentation
Annual General Meeting 2024 CEO presentation 8 May 2024 Footer
Slide 2: Forward looking statements
2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-lo
Slide 3: Camurus snapshot
3 Camurus snapshot Rapidly growing commercial Unique FluidCrystal® stage company technology platform Leader in opioid dependence treatment Commercially validated, with Buvidal® weekly and monthly depots with a broad range of applications Advancing late-stage pipeline Strong financial performance wit
Slide 4: Successful 2023 laid the foundation for continued profitable growth
4 Successful 2023 laid the foundation for continued profitable growth Towards global leadership in opioid dependence treatment Successful launch of Brixadi® in the US Positive results and progress in three Phase 3 programs NDA submission for Oclaiz™ (CAM2029) in acromegaly in the US Strong financial
Slide 5: Positive financial development
5 Positive financial development •Revenues •Profit before tax MSEK MSEK 2 000 600 549 1,717 400 1 500 200 1 000 957 73 0 601 500 -112 336 -200 -207 106 0 -400 -362 2019 2020 2021 2022 2023 2019 2020 2021 2022 2023
Slide 6: Progress towards Camurus' Vision 2027
6 Progress towards Camurus’ Vision 2027 •Status update end-2023 following one year of execution towards the five-year vision 5x 4 ~50% Five-fold revenue growth Establishment Approvals for four R&D Operating margin around 50% (from 2022) of US commercial infrastructure pipeline programs 5x revenue gr
Slide 7: Leading FluidCrystal extended-release technology
7 Leading FluidCrystal® extended-release technology Rapid onset & long-acting release Compatible with prefilled syringes, autoinjector Easy and convenient administration pens, and other advanced devices Broad application across substance classes Growing intellectual property portfolio Inje
Slide 8: Broad and diversified product portfolio and pipeline
8 Broad and diversified product portfolio and pipeline Phase 1 Phase 2 Phase 3 Registration Market Product on the market Buvidal® Opioid dependence Brixadi ® Opioid use disorder (USA)1 Pipeline programs CAM2029 Acromegaly CAM2029 Gastroenteropancreatic neuroendocrine tumors CAM2029 Polycystic liver
Slide 9: Buvidal – game changing opioid dependence treatment
9 Buvidal – game changing opioid dependence treatment Weekly and monthly, subcutaneous buprenorphine for individualized treatment of opioid dependence within a framework of medical, social and psychological treatment in adults and adolescents 16 years or over1 Demonstrated benefits to patients and s
Slide 10: Brixadi and Buvidal – well differentiated
10 Brixadi and Buvidal – well differentiated •Flexible dosing and posology ‒ Weekly and monthly dosing LAI features1 ‒ Multiple dose options ‒ Choice of multiple injection sites ‒ Thin needle and small dose volumes Weekly dosing – – •Easy switch from daily medication Monthly dosing Multiple
Slide 11: Continued strong growth of Buvidal/Brixadi
11 Continued strong growth of Buvidal/Brixadi •Towards global leadership in opioid •Buvidal product sales development dependence treatment MSEK 1500 ‒ Buvidal/Brixadi available across four continents 1299 ‒ Approximately 50,000 patients globally end 2023 •Growing evidence base 1000 936 ‒ Treatment e
Slide 12: Accelerated growth of Brixadi in the US following successful launch
12 Accelerated growth of Brixadi in the US following successful launch in Sep 2023 •Braeburn responsible for US commercialization •Brixadi royalty development ‒ Focused commercial organization of over 100 people MSEK 30 •Wide access to Brixadi for the treatment of OUD 26 ‒ Available in all US states
Slide 13: Octreotide SC depot
13 Octreotide SC depot CAM2029 under development in three serious, rare disease indications • Acromegaly • Gastroenteropancreatic neuroendocrine tumors (GEP-NET) • Polycystic liver disease (PLD) •Designed for enhanced efficacy, patient convenience and quality of life
Slide 14: Comprehensive clinical study program for CAM2029
14 Comprehensive clinical study program for CAM2029 21 Oct 2024 NDA filing MAA filing NDA approval 1 Phase 3 RCT ACRO US ACRO EU decision ACRO 5 completed Phase 1 and 2 clinical trials 2 Phase 3 LST Study extension characterizing Est. NDA filing PK, PD and Fully recruited GEP-NET safety in healthy s
Slide 15: Positive results from ACROINNOVA 1
15 Positive results from ACROINNOVA 1 – CAM2029 provided robust biochemical control •ACROINNOVA 1 trial design •Superiority achieved •CAM2029 improved ‒ 24-week, randomized, double ‒ Significantly more patients ‒ Treatment convenience blind, placebo-controlled trial achieved IGF-1 control with ‒ Acr
Slide 16: Positive interim results from ACROINNOVA 2
16 Positive interim results from ACROINNOVA 2 •ACROINNOVA 2 trial design •Improved acromegaly •ACROINNOVA 2 interim results ‒ 52-week, open-label safety trial with symptoms with CAM2029 ‒ Reinforcing long-term safety and further extension effectiveness observed in ACROINNOVA 1 •Patient population 1
Slide 17: Completed patient recruitment in Phase 3 SORENTO study
17 Completed patient recruitment in Phase 3 SORENTO study of CAM2029 in GEP-NET Enrollment of 332 patients across 12 countries exceeding randomization target (302) Largest ever controlled clinical study with somatostatin receptor ligand SORENTO designed to demonstrate superiority in progressio
Slide 18: CAM2029 progressing towards market with upcoming key milestones 2024/25
18 CAM2029 progressing towards market with upcoming key milestones 2024/25 Pivotal randomized placebo controlled Subcutaneous Octreotide Randomized Polycystic liver Safety and efficacy and long-term safety trials in acromegaly Efficacy in Neuroendocrine TumOrs TriAl with subcutaneous Octreotide Po
Slide 19: High market potential for CAM2029
19 High market potential for CAM2029 – largest opportunity in GEP-NET •Attractive specialty pharma opportunity ‒ Blockbuster potential in NET ‒ Highly concentrated target audiences ‒ Differentiated product features ‒ Switch from established first-line treatments • CAM2029 peak sales estimates from t
Slide 20: Significant near-term opportunities
20 Significant near-term opportunities Establish global leadership in opioid dependence treatment Expected US market approval for Oclaiz™ (CAM2029) in acromegaly Topline results from SORENTO and POSITANO studies of CAM2029 in GEP-NET and PLD Inorganic growth and diversification through busin
Slide 21: New Camurus headquarter December 2024
21 New Camurus headquarter December 2024 “The Loop” at Science Village, Lund ‒ Capacity to host >200 Camurus employees ‒ Strong sustainability profile building (LEED level gold certified)
Slide 22: Continuing our sustainability journey
22 Continuing our sustainability journey •Camurus’ commitment to improve the lives of patients with severe and chronic diseases has a • Net zero GHG-emissions clear sustainability perspective. (scope 1, 2 and 3). From 2045 residual GHG- emissions will be offset •Our ambition is to create patient and
Slide 23: Thank you!
Thank you! Camurus AB │ Ideon Science Park, SE-223 70 Lund, Sweden P +46 46 286 57 30 │ info@camurus.com │ camurus.com
Slide 24: Shareholders and analyst coverage
24 Shareholders and analyst coverage Shareholders as of 30 April 2024 Number of shares % of capital % of votes Sandberg Development AB 21,875,692 38.0 38.0 Fjärde AP-fonden 2,610,766 4.5 4.5 Analysts Avanza Pension 1,835,773 3.2 3.2 Carnegie Swedbank Robur Fonder 1,799,360 3.1 3.1 Erik Hultgård Fred
Slide 25: Experienced and committed management team
25 Experienced and committed management team Fredrik Tiberg, PhD Education: M.Sc. in Chem. Eng., Lund Institute of Technology, PhD Jon Garay Alonso Education: Bachelor in Business Administration by Universidad President & CEO, CSO and Assoc. Prof. Physical Chemistry, Lund University. Chief Financial